Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Translational Lung Cancer Research|May 13, 2024
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in <i>EGFR</i> exon 18Yuanyuan Zhang, Hao Zeng, Chang Qi, et al.
Translational Lung Cancer Research|February 4, 2020
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastasesZoltan Lohinai, Zsolt Megyesfalvi, Kenichi Suda, et al.
Thoracic Cancer|March 12, 2021
Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistanceMasaya Nishino, Kenichi Suda, Takamasa Koga, et al.
Thoracic Cancer|November 12, 2015
Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobeKenji Tomizawa, Kenichi Suda, Toshiki Takemoto, et al.
Clinical Lung Cancer|October 27, 2021
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic CarcinomasToshio Fujino, Kenichi Suda, Kazuko Sakai, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2020
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Keiko Obata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2019
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In VitroToshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, et al.
Clinical Lung Cancer|April 4, 2026
Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR MutationKenichi Suda, Kazuko Sakai, Masaoki Ito, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2021
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancerShuta Ohara, Kenichi Suda, Toshio Fujino, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitroMasaya Nishino, Kenichi Suda, Yoshihisa Kobayashi, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Translational Lung Cancer Research|May 13, 2024
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in <i>EGFR</i> exon 18Yuanyuan Zhang, Hao Zeng, Chang Qi, et al.
Translational Lung Cancer Research|February 4, 2020
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastasesZoltan Lohinai, Zsolt Megyesfalvi, Kenichi Suda, et al.
Thoracic Cancer|March 12, 2021
Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistanceMasaya Nishino, Kenichi Suda, Takamasa Koga, et al.
Thoracic Cancer|November 12, 2015
Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobeKenji Tomizawa, Kenichi Suda, Toshiki Takemoto, et al.
Clinical Lung Cancer|October 27, 2021
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic CarcinomasToshio Fujino, Kenichi Suda, Kazuko Sakai, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2020
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Keiko Obata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2019
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In VitroToshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, et al.
Clinical Lung Cancer|April 4, 2026
Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR MutationKenichi Suda, Kazuko Sakai, Masaoki Ito, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2021
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancerShuta Ohara, Kenichi Suda, Toshio Fujino, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitroMasaya Nishino, Kenichi Suda, Yoshihisa Kobayashi, et al.
Pageof 13